R7E 주식 개요 임상 단계의 바이오 제약 회사인 사이빈은 정신 건강 질환 환자를 위한 사이키델릭 기반 치료제를 개발하는 데 주력하고 있습니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Cybin 과거 주가 현재 주가 US$9.40 52주 최고치 US$19.19 52주 최저치 US$6.16 베타 0.92 1개월 변경 -4.57% 3개월 변경 사항 13.25% 1년 변경 사항 -38.47% 3년 변화 -72.05% 5년 변화 n/a IPO 이후 변화 -85.45%
최근 뉴스 및 업데이트
Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder Nov 19
Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results Nov 13
Cybin Inc. Announces Executive Appointments Oct 01
Cybin Inc. Provides Corporate Update on Upcoming Clinical Milestones Sep 21
Insufficient new directors Sep 01
Forecast to breakeven in 2027 Aug 22 더 많은 업데이트 보기
Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder Nov 19
Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results Nov 13
Cybin Inc. Announces Executive Appointments Oct 01
Cybin Inc. Provides Corporate Update on Upcoming Clinical Milestones Sep 21
Insufficient new directors Sep 01
Forecast to breakeven in 2027 Aug 22 Cybin Inc. Announces the Realignment of the Composition of Governance and Nominating Committee, and Compensation Committee
Cybin Inc., Annual General Meeting, Aug 27, 2024 Jul 06
Co-Founder recently bought €60k worth of stock Jun 30
No longer forecast to breakeven Jun 26
Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development Jun 13
Forecast to breakeven in 2027 Mar 31 Cybin Inc. announced that it has received $150 million in funding from a group of investors Mar 20
New minor risk - Profitability Mar 17
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder Mar 16
Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder Mar 15
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design Mar 14 Cybin Inc. announced that it expects to receive $150 million in funding from a group of investors Mar 13
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder Jan 23
Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028 Jan 09
Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting Dec 07
Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses Nov 30 Cybin Inc. has completed a Composite Units Offering in the amount of $30 million. Nov 15
New major risk - Revenue and earnings growth Nov 04
Cybin Inc. Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose Nov 01
New major risk - Shareholder dilution Oct 24 Cybin Inc. completed the acquisition of Small Pharma Inc. (TSXV : DMT).
Cybin Inc. Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder Sep 22 Cybin Inc. agreed to acquire Small Pharma Inc. (TSXV : DMT) for $23.2 million. Aug 30
Cybin Inc. Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial Aug 18
New major risk - Financial position Aug 15 Cybin Inc. has completed a Composite Units Offering in the amount of $8.25 million. Aug 03
Cybin Inc. Announces Phase 2 Cohort 5 Dosing Completion of Cyb003 in Major Depressive Disorder Jul 25
Cybin Inc. Announces Publication of Sponsored Feasibility Study Validating Kernel's Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain Jul 23
Cybin Inc. Announces the Development of Scalable Psychedelic Facilitation Training Program, Embarkct Jul 13
New major risk - Share price stability Jul 01
Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer, Effective July 1, 2023 Jun 30
Cybin Inc., Annual General Meeting, Aug 29, 2023 Jun 27
Cybin Announces Scientific Management Transition Jun 06 Cybin Inc. announced that it expects to receive CAD 41 million in funding from Lincoln Park Capital, LLC Jun 01
Cybin Inc. Initiates First-In-Human Dosing of CYB004 in Phase 1 Clinical Trial May 25
Cybin Inc. Announces Last Subject Dosed in Part B of Its Phase 1 CYB004-E Trial May 10
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004 Feb 02
Cybin Inc. Announces Promising Results from Sponsored Kernel Flow Feasibility Study Measuring Psychedelic Effects on the Brain Jan 19
Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004 Jan 13
Cybin Inc. Outlines Upcoming Priorities and Milestones for Its Clinical Development Programs Jan 10
High number of new and inexperienced directors Nov 16
Cybin Inc. Provides Progress Update on Its Cyb004-E Phase 1 Trial Nov 11
Cybin Achieves Research and Development Milestones Ahead of Projected Timelines Sep 21
Cybin Inc. Announces First Participants Dosed in Its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder Aug 31
Cybin Inc. and Clinilabs Drug Development Corporation Announces U.S. Drug Enforcement Agency Grant A Schedule I License to Support the First-In-Human Phase 1/2A Clinical Trial of CYB003 Aug 18
Cybin Inc. Announces Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2A Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder Jul 13
Independent Director recently bought €54k worth of stock Jul 02
Cybin Inc. Receives Fda Ind Clearance for Its Phase 1/2A Clinical Trial Evaluating Cyb003 for the Potential Treatment of Major Depressive Disorder Jun 28
Cybin Inc., Annual General Meeting, Aug 15, 2022 Jun 17
Cybin Receives Institutional Review Board Approval for Its Phase 1/2A Clinical Trial Evaluating Cyb003 for the Treatment of Major Depressive Disorder Jun 10
Cybin Acquires DMT Clinical Study from Entheon Biomedical Jun 09
Cybin Inc. Submits IND Application to FDA for its Phase 1/2a First-In-Human Trial of CYB003 for Treatment of Major Depressive Disorder Jun 01 Cybin and Kernel Announce Results from Kernel Flow Piloting of Feasibility Study Measuring Ketamine's Effects on the Brain May 10
Cybin Inc. Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine May 06
High number of new and inexperienced directors Apr 27
Cybin Inc. Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT Apr 14
Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain Apr 01
High number of new and inexperienced directors Mar 31
Cybin Announces Successful Completion of in Vivo Preclinical Studies for Its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial Mar 30
Cybin Inc. to Report Q3, 2022 Results on Feb 10, 2022 Jan 28
Institutional Review Board Grants Approval for Cybin Inc.'s Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain Jan 12
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for A Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing Covid-Related Distress Dec 01
Chief Operating Officer recently bought €86k worth of stock Nov 25
Cybin Awards Grant for Psychedelic Treatment Clinic At Lenox Hill Hospital to Benefit Underserved Communities Nov 24
Chief Legal Officer recently bought €102k worth of stock Aug 25
Cybin Files Two Additional International Patent Applications in Support of the Company’S Research Phase Programs Aug 20
Cybin Inc. Deleted from Other OTC Aug 06
Cybin Files its 13th Patent Application Jul 15
Cybin Announces Completion of Its 51St Pre-Clinical Psychedelic Molecule Study Jun 23
Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy Jun 09
Cybin Inc. Files an International Patent Application Further Strengthening Its Psychedelic Derivative Drug Development Candidates Across 153 Global Jurisdictions May 27
Cybin Inc. Files Its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms May 21
Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder May 19
Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003 Apr 27
Cybin Inc. Progresses Two Psychedelic Investigational New Drug Candidates and Announces Completion of its 20th Pre-Clinical Study Mar 18
Cybin Inc. Announces Executive Changes Feb 18
Chief Marketing Officer has left the company Feb 17
Chief Medical Officer has left the company Feb 17 주주 수익률 R7E DE Pharmaceuticals DE 마켓 7D 11.2% 2.2% 1.7% 1Y -38.5% -15.0% 9.4%
전체 주주 수익률 보기
수익률 대 산업: R7E 지난 1년 동안 -15 %를 반환한 German Pharmaceuticals 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: R7E 지난 1년 동안 9.4 %를 반환한 German 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is R7E's price volatile compared to industry and market? R7E volatility R7E Average Weekly Movement 16.2% Pharmaceuticals Industry Average Movement 5.6% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
안정적인 주가: R7E 의 주가는 지난 3개월 동안 German 시장과 비교해 변동성이 컸습니다.
시간에 따른 변동성: R7E 의 주간 변동성 ( 16% )은 지난 1년 동안 안정적이었지만 여전히 German 의 75%보다 높습니다. 주식.
회사 소개 임상 단계의 바이오 제약 회사인 사이빈은 정신 건강 질환 환자를 위한 사이키델릭 기반 치료제를 개발하는 데 주력하고 있습니다. 이 회사의 개발 파이프라인에는 주요 우울 장애(MDD) 치료를 위한 임상 1/2a상 및 알코올 사용 장애 전임상 시험 중인 중수화 실로시빈 유사체 CYB003, 범불안 장애 치료를 위한 임상 2상 시험을 완료한 중수화 디메틸트립타민(DMT) CYB004, 그리고 전신 불안 장애 치료를 위한 임상 2상 시험 중인 중수화 실로시빈 유사체 SPL028이 있습니다; 근육 내 및 정맥 내 임상 1상 시험을 완료한 주사 가능한 중수소화 DMT인 SPL028, MDD에 대한 임상 1상, 1b상 및 1/2a상을 완료한 SPL026, 신경염증 치료를 위한 전임상 단계에 있는 페닐아민 유도체인 CYB005, 그리고 연구용 사이키델릭 기반 화합물에 대한 파이프라인을 보유하고 있습니다. 이 회사는 환각 화합물 기반 치료제 개발을 위한 TMS 뉴로헬스 센터, 신경 활동을 측정하기 위한 커널 흐름 기술 사용을 위한 커널, 정신 건강 센터 설립을 위한 그린북 TMS와 연구 및 협력 계약을 맺고 있습니다.
자세히 보기 Cybin Inc. 기본 사항 요약 Cybin 의 수익과 매출은 시가총액과 어떻게 비교하나요? R7E 기본 통계 시가총액 €194.48m 수익(TTM ) -€83.37m 수익(TTM ) n/a
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) R7E 손익 계산서(TTM ) 수익 CA$0 수익 비용 CA$0 총 이익 CA$0 기타 비용 CA$123.69m 수익 -CA$123.69m
주당 순이익(EPS) -6.18 총 마진 0.00% 순이익 마진 0.00% 부채/자본 비율 0%
R7E 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/01/08 04:12 장 마감 주가 2025/01/08 00:00 수익 2024/09/30 연간 수익 2024/03/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Cybin Inc. 9 애널리스트 중 4 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 James Molloy Alliance Global Partners David Martin Bloom Burton & Co. Sumant Satchidanand Kulkarni Canaccord Genuity
6 더 많은 분석가 보기 
